Alpha Tau Medical Ltd. (DRTS) Research
Alpha Tau Medical Ltd. is a clinical-stage biotechnology company dedicated to the advancement and eventual commercialization of innovative cancer treatments. Their primary focus is on "Alpha DaRT" (Diffusing Alpha-Emitters Radiation Therapy), a novel approach designed to combat solid tumors. This therapeutic radiation technique is currently undergoing clinical evaluation for various solid malignancies, including skin, oral, pancreatic, and breast cancers, with development efforts primarily concentrated in Israel and the United States. Furthermore, Alpha DaRT is being explored in preclinical investigations for additional challenging cancers such as hepatic cell carcinoma, glioblastoma multiforme (a type of brain tumor), and lung cancer, among others. Established in 2015, the company maintains its headquarters in Jerusalem, Israel.
Market snapshot
- Symbol
- DRTS
- Price
- $9.78
- Day change
- +1.77%
- Market cap
- $883.4M
- P/E ratio
- -15.43x
- 52-week range
- 2.85-11.62
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $13.33
Recent news
- Alpha Tau Medical Stock Surges As Interim Brain Tumor Trial Data Sparks Rally
Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS) rose Monday after the company reported interim results from its U.S. trial of Alpha DaRT in patients with recurrent glioblastoma.
Peer companies
Recent insider activity
- Levy Raphi — S-Sale (17500 shares) on 2026-06-03
- Levy Raphi — S-Sale (15000 shares) on 2026-06-03
- Avruch Michael — trade (0 shares) on 2026-03-18
- Avruch Michael — trade (0 shares) on 2026-03-18
- Avruch Michael — trade (0 shares) on 2026-03-18
Open Alpha Tau Medical Ltd. (DRTS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.